CAJ | 학술논문

目的：对PfCP-2.9/PfCSP-2疟疾联合疫苗所诱发的特异性IgG抗体进行分析评价。方法将5只新西兰白兔分为两组，其中免疫组3只，非免疫组2只。免疫组接种PfCP-2.9/PfCSP-2疟疾联合疫苗，非免疫组注射生理盐水。连续3次免疫后，采集血液样本并经间接ELISA检测其IgG抗体水平。根据非免疫组兔的吸光度数值（A值）计算临界值。临界值=2.1×非疫苗免疫组兔A值均值。若免疫组兔吸光度值高于临界值，则被判定为疫苗可诱发特异性 IgG 抗体。结果疫苗可诱发针对PfCP-2.9和PfCSP-2重组蛋白IgG抗体，经4个稀释浓度（1∶100、1∶200、1∶400、1∶800）检测获得2只免疫组兔A值分别为0.629/0.544、0.548/0.443、0.479/0.378、0.410/0.281，均高于相应稀释浓度的临界值（0.019、0.017、0.016、0.020）；疫苗可诱发针对 PfCSP 的特异性 IgG 抗体（每孔包被4μg/ml 多肽），经4个稀释浓度（1∶100、1∶200、1∶400、1∶800）检测2只免疫组家兔A 值分别为0.308/0.152、0.194/0.080、0.110/0.040、0.060/0.025，均高于相应稀释浓度的临界值（0.027、0.019、0.018、0.018）；疫苗可诱发针对PfCSP的特异性IgG抗体（每孔包被10μg/ml多肽），经4个稀释浓度（1∶100、1∶200、1∶400、1∶800）检测获得2只免疫组家兔 A 值分别为0.333/0.129、0.221/0.086、0.133/0.048、0.075/0.029，均高于相应稀释浓度的临界值（0.048、0.038、0.036、0.036）；结论 PfCP-2.9/PfCSP-2疟疾联合疫苗可诱发高水平IgG抗体，该疫苗是安全、有效且耐受性良好。
목적：대PfCP-2.9/PfCSP-2학질연합역묘소유발적특이성IgG항체진행분석평개。방법장5지신서란백토분위량조，기중면역조3지，비면역조2지。면역조접충PfCP-2.9/PfCSP-2학질연합역묘，비면역조주사생리염수。련속3차면역후，채집혈액양본병경간접ELISA검측기IgG항체수평。근거비면역조토적흡광도수치（A치）계산림계치。림계치=2.1×비역묘면역조토A치균치。약면역조토흡광도치고우림계치，칙피판정위역묘가유발특이성 IgG 항체。결과역묘가유발침대PfCP-2.9화PfCSP-2중조단백IgG항체，경4개희석농도（1∶100、1∶200、1∶400、1∶800）검측획득2지면역조토A치분별위0.629/0.544、0.548/0.443、0.479/0.378、0.410/0.281，균고우상응희석농도적림계치（0.019、0.017、0.016、0.020）；역묘가유발침대 PfCSP 적특이성 IgG 항체（매공포피4μg/ml 다태），경4개희석농도（1∶100、1∶200、1∶400、1∶800）검측2지면역조가토A 치분별위0.308/0.152、0.194/0.080、0.110/0.040、0.060/0.025，균고우상응희석농도적림계치（0.027、0.019、0.018、0.018）；역묘가유발침대PfCSP적특이성IgG항체（매공포피10μg/ml다태），경4개희석농도（1∶100、1∶200、1∶400、1∶800）검측획득2지면역조가토 A 치분별위0.333/0.129、0.221/0.086、0.133/0.048、0.075/0.029，균고우상응희석농도적림계치（0.048、0.038、0.036、0.036）；결론 PfCP-2.9/PfCSP-2학질연합역묘가유발고수평IgG항체，해역묘시안전、유효차내수성량호。
Objective To analyze and evaluate the specific IgG antibodies level induced by PfCP-2.9/PfCSP-2 combination malaria vaccine. Methods Five New Zealand white rabbits were divided into two groups, three in vaccine immunized group, and two in non-vaccine immunized group. Vaccine immunized group was inoculated PfCP-2.9/PfCSP-2 combination malaria vaccine, non-vaccine immunized group was in-jected with saline. After 3 consecutive immunizations, blood samples were collected and tested by indirect ELISA to detect IgG antibody. Cut-off values were calculated in accordance with the absorbance value (A val-ue) obtained from non-vaccine immunized rabbits. Cut-off value=2.1× average A value of two non-vaccine im-munized rabbits. If absorbance values acquired from immunized rabbit were higher than the cut-off value, it was judged that the vaccine can induce specific IgG antibodies. Results Vaccines can induce specific IgG antibody against PfCP-2.9 and PfCSP-2 recombinant protein, after 4 level of serum dilution (1∶100, 1∶200, 1∶400, 1:800) detection, The A values from two vaccine immunized rabbits were 0.629/0.544, 0.548/0.443, 0.479/0.378, 0.410/0.281, higher than the cut-off value of the corresponding dilution (0.019, 0.017, 0.016, 0.020). Vaccine can induce specific IgG antibodies against PfCSP (per well coated 4 μg/ml polypeptide), af-ter 4 levels of serum dilution (1∶100, 1∶200, 1∶400, 1∶800) detection, The A values from two vaccine immu-nized rabbits were 0.308/0.152, 0.194/0.080, 0.110/0.040, 0.060/0.025, higher than the cut-off value of corre-sponding dilution (0.027, 0.019, 0.018, 0.018);vaccine can induce specific IgG antibody against PfCSP(per well coated with 10 ug/ml polypeptide) , after 4 level of serum dilution(1∶100, 1∶200, 1∶400, 1∶800) detection, A values from two vaccine immunized rabbits were 0.333/0.129, 0.221/0.086, 0.133/0.048,0.075/0.029, higher than the cut-off value of corresponding dilution (0.048, 0.038, 0.036, 0.036). Conclusion PfCP-2.9/PfCSP-2 malaria vaccine can induce high level of IgG antibody. It is a safe, effective and well-tolerated vaccine.